AVROBIO (NASDAQ:AVRO) Trading 1.6% Higher

Shares of AVROBIO, Inc. (NASDAQ:AVRO) were up 1.6% during mid-day trading on Monday . The company traded as high as $1.25 and last traded at $1.24. Approximately 156,514 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 272,440 shares. The stock had previously closed at $1.22.

AVROBIO Stock Performance

The business has a fifty day moving average of $1.26 and a 200-day moving average of $1.33. The firm has a market capitalization of $55.63 million, a P/E ratio of -12.40 and a beta of 1.24.

Institutional Investors Weigh In On AVROBIO

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Private Advisor Group LLC acquired a new position in AVROBIO during the 3rd quarter valued at about $33,000. Gabelli Funds LLC acquired a new stake in AVROBIO in the fourth quarter worth approximately $467,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in AVROBIO during the 4th quarter valued at $480,000. FNY Investment Advisers LLC increased its position in shares of AVROBIO by 77.8% during the 4th quarter. FNY Investment Advisers LLC now owns 400,000 shares of the company’s stock valued at $544,000 after purchasing an additional 175,000 shares during the period. Finally, Aldebaran Capital LLC bought a new stake in shares of AVROBIO in the 3rd quarter worth $724,000. 62.63% of the stock is currently owned by institutional investors.

AVROBIO Company Profile

AVROBIO, Inc, a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.